Press "Enter" to skip to content

New patent expiration for Gilead Sciences drug ATRIPLA

0
Copyright © DrugPatentWatch. Originally published at New patent expiration for Gilead Sciences drug ATRIPLA

Annual Drug Patent Expirations for ATRIPLA
Annual Drug Patent Expirations for ATRIPLA

Atripla is a drug marketed by Gilead Sciences and is included in one NDA. It is available from two suppliers. There are nine patents protecting this drug and one Paragraph IV challenge.

Drug patent litigation for ATRIPLA.

This drug has one hundred and fourteen patent family members in thirty-one countries.

The generic ingredient in ATRIPLA is efavirenz; emtricitabine; tenofovir disoproxil fumarate. Two suppliers are listed for this compound. Additional details are available on the efavirenz; emtricitabine; tenofovir disoproxil fumarate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent expiration for Gilead Sciences drug ATRIPLA
    Get the DrugPatentWatch Daily Briefing

    ✓ Patent Expirations and Generic Entry

    ✓ Insightful Articles & Case Studies

    ✓ Patent Litigation & Challenges

    ✓ 505(b)(2) & Biosimilars

    ✓ Industry Trends

    DrugPatentWatch - Make Better Decisions